Evaluation and Management of Bone Pain in Lupus Patients

Introduction to Lupus Management

The American College of Rheumatology recommends immediate evaluation for opportunistic infection, particularly cytomegalovirus (CMV), in lupus patients with new-onset bone pain and concurrent viral symptoms, as CMV can mimic active SLE and is reported in 18-44% of lupus patients, especially those on high-dose corticosteroids 1

Testing for CMV antigenaemia is urgently recommended, as this infection can present with bone pain and viral symptoms while mimicking lupus flare, particularly in patients receiving immunosuppressive therapy 2, 1
A complete blood count is necessary to evaluate for severe lymphopenia or neutropenia, both of which significantly increase infection risk 3, 4
Immunoglobulin levels, specifically IgG, IgG3, and IgG4, should be assessed, as low levels are associated with increased infection susceptibility 2
Disease activity markers, including anti-dsDNA, C3, C4, complete blood count, creatinine, proteinuria, and urine sediment, are used to differentiate infection from lupus flare 5

The Centers for Disease Control and Prevention recommends tuberculosis screening according to local guidelines, as TB frequency ranges from 2.5-13.8% in endemic areas 2, 3
Hepatitis B and C screening is recommended based on risk factors before intensifying immunosuppression 3, 4
Vaccination with inactivated vaccines, such as influenza and pneumococcal, is recommended when disease is inactive, following CDC guidelines for immunosuppressed patients 3, 4

For musculoskeletal pain without organ-threatening disease, the European League Against Rheumatism recommends NSAIDs for intermittent joint pain and low-dose glucocorticoids for persistent pain 7
Hydroxychloroquine should be optimized at ≤5 mg/kg real body weight as the cornerstone therapy 7, 5

Calcium and vitamin D supplementation is recommended for patients on long-term glucocosteroids to prevent bone loss 6, 7, 5

Continuous infection risk assessment is necessary at follow-up visits, considering severe neutropenia, lymphopenia, and low IgG levels 3, 4
Disease activity monitoring using validated indices, such as BILAG, ECLAM, or SLEDAI, is recommended at each visit 6, 5